Skip to main
TDOC
TDOC logo

Teladoc (TDOC) Stock Forecast & Price Target

Teladoc (TDOC) Analyst Ratings

Based on 36 analyst ratings
Hold
Strong Buy 17%
Buy 25%
Hold 56%
Sell 0%
Strong Sell 3%

Bulls say

Teladoc Health Inc. has demonstrated a rebound in key metrics with BetterHelp achieving sequential membership growth after five quarters of declines, indicating potential stabilization and recovery within its user base. The Integrated Care segment added 800 clients in January, reflecting ongoing demand and expansion within the market. Additionally, the company reported a significant improvement in GAAP EPS to ($0.25), attributed to effective expense management, and sees promising growth potential from a burgeoning market and an increase in paid memberships, supported by the expansion of virtual care services.

Bears say

Teladoc Health is facing a negative outlook as its total revenue declined by 3.0% year-over-year, primarily due to a significant contraction in the BetterHelp segment, which saw a revenue drop of 9.5%. Additionally, the company’s guidance indicates expectations of continued decline in BetterHelp revenue and slight margin compression, further compounding concerns around profitability. The prolonged decrease in BetterHelp users over the last five quarters, coupled with management's cautious stance on user growth, underscores challenges in achieving a rebound in revenue performance.

Teladoc (TDOC) has been analyzed by 36 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 25% recommend Buy, 56% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teladoc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teladoc (TDOC) Forecast

Analysts have given Teladoc (TDOC) a Hold based on their latest research and market trends.

According to 36 analysts, Teladoc (TDOC) has a Hold consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.63, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.63, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teladoc (TDOC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.